201 related articles for article (PubMed ID: 23810244)
41. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation.
Çiftçiler R; Göker H; Demiroğlu H; Haznedaroğlu İC; Sayınalp N; Aksu S; Özcebe O; Büyükaşık Y
Turk J Haematol; 2021 Feb; 38(1):33-40. PubMed ID: 32539315
[TBL] [Abstract][Full Text] [Related]
43. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
44. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
45. Multiple myeloma in elderly patients: prognostic factors and outcome.
Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
[TBL] [Abstract][Full Text] [Related]
46. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma.
Ailawadhi S; Abdelhalim AN; Derby L; Mashtare TL; Miller KC; Wilding GE; Alberico RA; Gottlieb R; Klippenstein DL; Lee K; Chanan-Khan AA
Cancer; 2010 Jan; 116(1):84-92. PubMed ID: 19862816
[TBL] [Abstract][Full Text] [Related]
47. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
48. Validation of the rheumatic disease comorbidity index.
England BR; Sayles H; Mikuls TR; Johnson DS; Michaud K
Arthritis Care Res (Hoboken); 2015 May; 67(6):865-72. PubMed ID: 25186344
[TBL] [Abstract][Full Text] [Related]
49. The impact of frontline risk-adapted strategy on the overall survival of patients with newly diagnosed multiple myeloma: an analysis of the Singapore multiple myeloma study group.
Tan D; Ong KH; Koh LP; Wong SS; Khin MT; Lee LH; Goh YT; Chng WJ
Eur J Haematol; 2012 Aug; 89(2):136-44. PubMed ID: 22553948
[TBL] [Abstract][Full Text] [Related]
50. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
51. Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma.
Zhuang J; Da Y; Li H; Han B; Wan X; Zhu T; Chen M; Duan M; Xu Y; Zhao Y; Shen T; Wua Y; Zhou D
Leuk Res; 2014 Feb; 38(2):188-93. PubMed ID: 24342807
[TBL] [Abstract][Full Text] [Related]
52. Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Cho H; Yoon DH; Lee JB; Kim SY; Moon JH; Do YR; Lee JH; Park Y; Lee HS; Eom HS; Shin HJ; Min CK; Kim JS; Jo JC; Kang HJ; Mun YC; Lee WS; Lee JJ; Suh C; Kim K;
Am J Hematol; 2017 Dec; 92(12):1280-1286. PubMed ID: 28833417
[TBL] [Abstract][Full Text] [Related]
53. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
54. Multiple myeloma international staging system: "staging" or simply "aging" system?
Bataille R; Annweiler C; Beauchet O
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):635-7. PubMed ID: 24035714
[TBL] [Abstract][Full Text] [Related]
55. The treatment outcome of multiple myeloma patients ineligible for hematopoietic transplantation--a single institutional experience in Taiwan.
Huang TC; Chen JH; Wu YY; Chang PY; Dai MS; Chao TY; Kao WY; Chen YC; Ho CL
Ann Hematol; 2015 Jan; 94(1):107-15. PubMed ID: 25047657
[TBL] [Abstract][Full Text] [Related]
56. Comorbidity measurement in patients with laryngeal squamous cell carcinoma.
Castro MA; Dedivitis RA; Ribeiro KC
ORL J Otorhinolaryngol Relat Spec; 2007; 69(3):146-52. PubMed ID: 17264530
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ozaki S; Handa H; Saitoh T; Murakami H; Itagaki M; Asaoku H; Suzuki K; Isoda A; Matsumoto M; Sawamura M; Sunami K; Takezako N; Hagiwara S; Kuroda Y; Chou T; Nagura E; Shimizu K
Ann Hematol; 2019 Jul; 98(7):1703-1711. PubMed ID: 31049648
[TBL] [Abstract][Full Text] [Related]
58. Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.
Gkotzamanidou M; Kastritis E; Gavriatopoulou MR; Nikitas N; Gika D; Mparmparousi D; Matsouka C; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):409-13. PubMed ID: 21903504
[TBL] [Abstract][Full Text] [Related]
59. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents.
Shang Y; Jin Y; Liu H; Ding L; Tong X; Tu H; Zang L; Lin C; Hu J; Zhou F
Hematol Oncol; 2022 Apr; 40(2):212-222. PubMed ID: 34860428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]